Mesenchymal mode of migration participates in pulmonary metastasis of mouse osteosarcoma LM8
- 26 September 2010
- journal article
- Published by Springer Science and Business Media LLC in Clinical & Experimental Metastasis
- Vol. 27 (8), 619-630
- https://doi.org/10.1007/s10585-010-9352-x
Abstract
The outcomes of osteosarcoma patients still remain poor because of intractable pulmonary metastasis. We previously established a highly metastatic osteosarcoma cell line, LM8 from Dunn mouse osteosarcoma by in vivo selection. We herein aimed to clarify the characteristic biological features related with high metastatic potential and new target molecules to suppress pulmonary metastasis of osteosarcoma, using this syngeneic spontaneous metastatic model. LM8 cells acquired fibroblastic morphology with striking filopodia on the cell surface. Immunostaining showed faint stress fiber formation and peripherally localized integrin β1, and biochemical analyses showed the activated Cdc42 and autophosphorylation of focal adhesion kinase (FAK) in LM8 cells when compared to Dunn cells. LM8 cells had activated motility in single cell migration mode. LM8 migration was increased by a Rho-associated kinase (ROCK) inhibitor, Y-27632, while decreased by Cdc42 silencing using RNA interference system. We found that a clinically approved camptothecin analog, irinotecan suppressed the migration, Cdc42 activity, and autophosphorylation of FAK, and attenuated integrin β1 distribution selectively in LM8 cells. Daily oral administration of irinotecan significantly reduced the rate and size of pulmonary metastasis in syngeneic C3H mice. The fibroblastic morphology and activated cell migration with the dependency on Cdc42 but not Rho-ROCK signaling pathway argued that LM8 moved in mesenchymal mode of cell migration. This activated mesenchymal migration was a key component of the pulmonary metastasis of LM8 cells. The inhibition of mesenchymal migration by irinotecan, in addition to its cytotoxic effects, might be effective in preventing pulmonary metastasis of osteosarcoma.This publication has 39 references indexed in Scilit:
- Rho GTPases in cancer cell biologyFEBS Letters, 2008
- Improvement in Histologic Response But Not Survival in Osteosarcoma Patients Treated With Intensified Chemotherapy: A Randomized Phase III Trial of the European Osteosarcoma IntergroupJNCI Journal of the National Cancer Institute, 2007
- Cell migration in tumorsCurrent Opinion in Cell Biology, 2005
- Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discoveryTrends in Pharmacological Sciences, 2005
- Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose MethotrexateJournal of Clinical Oncology, 2005
- Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651Journal of Clinical Oncology, 2003
- Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivoInternational Journal of Cancer, 2003
- Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeletonThe EMBO Journal, 1999
- The pathogenesis of cancer metastasisNature, 1980
- HISTOLOGY OF SOME NEOPLASMS AND NON-NEOPLASTIC LESIONS FOUND IN WILD MICE MAINTAINED UNDER LABORATORY CONDITIONS.1963